Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Policy News

Stay updated on ESMO’s policy work on oncology research, cancer prevention, access to treatments, universal health coverage and many more topics by following the news below

political initiatives

Policy News

For a Healthier Europe

ESMO Director of Public Policy, Professor Jean-Yves Blay, speaks to leading media outlet Euractiv ahead of the EU 2024 elections about the role of oncologists in delivering Europe’s Beating Cancer Plan during the new EU mandate and the upcoming Hungarian EU Presidency

Policy News

ESMO Continues With Its Efforts to Secure the Timely Delivery of Innovative Medicines for Patients With Cancer and Prevent Medicines Shortages

Ahead of the plenary vote in the European Parliament (EP), held on 10 April 2024, ESMO wrote to the Political Groups Coordinators on the EP’s Committee on the Environment, Public Health and Food Safety (ENVI) to welcome its reports as a positive step towards reforming the European Union’s general pharmaceutical legislation, as it provides a once in a generation opportunity to improve the availability, accessibility and affordability of medicines for both cancer and rare cancer patients in the EU

Policy News

Medical Oncologists Incredulous at the Commission’s Latest Backtracking on the Evaluation of the EU Tobacco Products Directive

Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation

Policy News

ESMO Contributes to Penultimate Meeting on the WHO Pandemic Accord

As the negotiations to increase global health security are nearing an end, ESMO reiterates the importance of strengthening the provision of secondary and tertiary healthcare services during pandemics to avoid leaving millions of patients with cancer behind

Policy News

ESMO to Present ESMO-MCBS at Key HTA Conference, Aiming to Improve Patient Access to Innovative Cancer Treatments

The European Society for Medical Oncology (ESMO) will be represented at the high-level conference From Theory to Practice: Implementing the EU Health Technology Assessment Regulation , which will take place in Seville on 22 November 2023, where Dr Teresa Amaral will present the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) as part of a stakeholder panel

Policy News

ESMO Works on Ensuring Patient Access to Clinical Trials Utilising In-Vitro Diagnostics

The European Society for Medical Oncology (ESMO) has raised concerns about the unforeseen impact of the implementation of the European Union’s (EU) Regulation on In Vitro Diagnostic Medical Devices (IVDR) on patient access to clinical trials utilising in-vitro diagnostics, with EU Commissioner for Health Stella Kyriakides, and called for concrete solutions that benefit cancer patients.

Policy News

ESMO Calls for Secondary and Tertiary Health Care Services for Cancer Patients to Be Prioritized in the WHO Pandemic Accord

ESMO delivered a statement during the first joint meeting between the Intergovernmental Negotiating Body (INB) and the WHO International Health Regulations Working Group, requesting that the inclusion of wording on access to secondary and tertiary healthcare services - already included in the text of the International Health Regulations (IHR) - also be included in the ‘Pandemic Accord’ (WHO CA+).

Policy News

New ESMO Public Policy Committee (PPC) holds kick-off meeting

The recently launched Public Policy Committee (PPC), with members from Peru through to Australia and representing all major cancer types, of the European Society for Medical Oncology (ESMO) held its first meeting virtually on 5 June 2023.

Policy News

European Parliament’s Position on the “Asbestos at Work” Directive Reflects ESMO’s Advocacy to Strengthen Worker Protection Against Asbestos and Reduce the Rates of Cancer

The revision of the EU’s Asbestos at Work Directive is set to enhance the protection of workers in Europe against asbestos, which is a highly dangerous carcinogenic substance. ESMO’s efforts to establish a robust exposure limit of 1,000 fibres per m3 and use more modern measuring methods are reflected in the European Parliament’s position.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.